Pharma Mar SA 2020 SR
The report highlights Pharma Mar Group's 2020 performance, focusing on oncology, diagnostics, and virology, including the launch of COVID-19 diagnostic kits and clinical trials for plitidepsin. The company achieved a significant revenue increase and maintained a strong commitment to R&D, ranking first in Spain for R&D investment per employee. Key environmental achievements include a reduction in daily water use and the implementation of ISO 45001 for health and safety. Socially, the group focused on talent retention, with women making up 44.2% of management and 36.4% of the Board.
Company: Pharma Mar SA
Sector: Manufacturing
Country: Spain
Year: 2020
Type: SR
Pages: 80
Back to company
Pharma Mar SA
Consolidated Non-Financial Information Statement
The report highlights Pharma Mar Group's 2020 performance, focusing on oncology, diagnostics, and virology, including the launch of COVID-19 diagnostic kits and clinical trials for plitidepsin. The company achieved a significant revenue increase and maintained a strong commitment to R&D, ranking first in Spain for R&D investment per employee. Key environmental achievements include a reduction in daily water use and the implementation of ISO 45001 for health and safety. Socially, the group focused on talent retention, with women making up 44.2% of management and 36.4% of the Board.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Published
Feb 26, 2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women on Board
Women in Management
Employees